Ricerca avanzata

Home > Riviste > Minerva Cardioangiologica > Fascicoli precedenti > Minerva Cardioangiologica 2014 Giugno;62(3) > Minerva Cardioangiologica 2014 Giugno;62(3):229-34



Rivista sulle Malattie del Cuore e dei Vasi

Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752

Periodicità: Bimestrale

ISSN 0026-4725

Online ISSN 1827-1618


Minerva Cardioangiologica 2014 Giugno;62(3):229-34


Treatment of coronary bifurcation lesions with bioresorbable vascular scaffolds

Capranzano P. 1, 2, Gargiulo G. 1, Capodanno D. 1, 2, Longo G. 1, Tamburino C. 1, Ohno Y. 1, Attizzani G. F. 1, La Manna A. 1, Di Salvo M. 1, Francaviglia B. 1, Grasso C. 1, Sgroi C. 1, Tamburino C. 1, 2

1 Division of Cardiology, Ferrarotto Hospital, University of Catania, Catania, Italy;
2 Excellence Through Newest, Advances (ETNA) Foundation, Catania, Italy

AIM: Aim of the study was to report on the feasibility and early safety and efficacy of Absorb everolimus-eluting bioresorbable vascular scaffold (BVS) for coronary artery bifurcations (CABs) treatment at a single high-volume center.
METHODS: All patients treated with Absorb implantation at our institution from March 2013 to March 2014 were enrolled in the prospective, single-center, ongoing, all-comers registry, which has the main purpose of evaluating the safety and efficacy of Absorb implantation in unselected patients treated in daily practice. In-hospital and at follow-up clinical outcomes of 46 patients undergoing treatment with Absorb in 46 CAB lesions were reported in the present study.
RESULTS: Treated CAB lesions involved the left main in 13.0% of cases, the left anterior descending artery in 65.0%, the left circumflex in 19.6%, and the right coronary artery in 2.2%. Bifurcations were classified as true (47.8%) and non-true (52.2%) according to the Medina classification. The provisional and the two-BVS techniques were used in 78.3% and 21.7%, respectively. Two-BVS techniques included: mini-crush 13.0%; reverse culotte 2.2%; T-stenting 2.2%; and V-stenting 4.3%. No in-hospital adverse events occurred. At 6 months no adverse events occurred. Only one case of target lesion revascularization was observed at day 227. No stent thrombosis occurred during follow-up.
CONCLUSION: Our preliminary experience suggested that CABs treatment with Absorb is feasible and associated with promising immediate and short-term clinical outcomes. However, larger studies with long-term follow-up are needed to adequately address the safety and efficacy of BVS use in CABs.

lingua: Inglese


inizio pagina